Key result
Biodegradable septal occluders approach routine use in congenital heart disease while vascular stents remain investigational.
Why the study?
Lifelong persistence of metallic stents and nitinol occluders can complicate reinterventions, limit imaging, and interfere with somatic growth in congenital heart disease.
Do biodegradable stents and occluders provide effective temporary mechanical support while preserving future interventional options in patients with congenital heart disease?
Do biodegradable stents and occluders provide effective temporary mechanical support while preserving future interventional options in patients with congenital heart disease?
Biodegradable septal occluders are closer to routine clinical use in congenital heart disease, while biodegradable vascular stents remain investigational and require further long-term studies.
Answers are grounded in this paper and cite their sources.
Moves biodegradable occluders nearer routine congenital use; leaves vascular stent durability open for prospective pediatric trials.
Congenital heart disease (CHD) often requires device implantation during childhood, when somatic growth and changing haemodynamics place particular demands on permanent implants. Metallic stents and nitinol occluders are effective, but their lifelong persistence can complicate repeat interventions, limit imaging surveillance, and interfere with growth-related remodelling. This review examines the rationale, current evidence, biomechanical constraints, and translational challenges of biodegradable stents and occluders in CHD. These devices aim to provide temporary mechanical support followed by controlled resorption, thereby reducing the burden of permanent foreign material and preserving future interventional options. Translation to congenital practice is, however, not straightforward, as early structural integrity must be balanced against predictable degradation, adequate endothelialisation, and compatibility with somatic growth. Experience from adult coronary bioresorbable scaffolds cannot be directly extrapolated to paediatric anatomies or timelines. Biodegradable septal occluders have accumulated more clinical experience and appear closer to routine use, whereas biodegradable vascular stents remain largely investigational and lack sufficient long-term outcome data to support broader adoption. Further long-term studies in paediatric and congenital populations are needed before biodegradable implants can be recommended as standard alternatives to permanent devices in CHD.
No takes yet. Share an insight, caveat, or question.
Özkök et al. (2026) conducted a review in Congenital heart disease (CHD). Biodegradable stents and occluders vs. Metallic stents and nitinol occluders was evaluated. Biodegradable septal occluders are closer to routine use in congenital heart disease, whereas biodegradable vascular stents remain investigational and lack sufficient long-term outcome data.
Synapse has enriched 10 related papers. Consider them for comparative context: